Indian J Pharm Close
 

Figure 3: Percentage retention in control, scopolamine (SCO; 3 mg/kg ip), tacrine (TAC; 5 mg/kg po) plus scopolamine (SCO) and rivastigmine (RIVA; 5 mg/kg po) plus scopolamine (SCO) treated groups for (a) acquisition and (b) consolidation. @P < 0.05, signifi cantly different from control; *P < 0.05, **P < 0.01, signifi cantly different from scopolamine treated group; ANOVA (one-way) followed by Newman–Keuls test

Figure 3: Percentage retention in control, scopolamine (SCO; 3 mg/kg ip), tacrine (TAC; 5 mg/kg po) plus scopolamine (SCO) and rivastigmine (RIVA; 5 mg/kg po) plus scopolamine (SCO) treated groups for (a) acquisition and (b) consolidation. @P < 0.05, signifi cantly different from control; *P < 0.05, **P < 0.01, signifi cantly different from scopolamine treated group; ANOVA (one-way) followed by Newman–Keuls test